Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timely recovery after subclinical heart failure (TREASURE)
2022-503135-33-00Phase 4Authorised
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of valsartan, perindopril, nitroglycerin and albumin (human) in heart failure (HF) and diastolic dysfunction, sponsored by Maastricht University Medical Center+. Primary endpoints: Left ventricular hypertrophy, Concentric remodeling and 3 more. Planned start Jul 2023; status: authorised.
02
Drugs
valsartanperindoprilnitroglycerinalbumin (human)
03
Conditions
heart failure (HF)diastolic dysfunction
Beyond the preview
Go deeper on 2022-503135-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503135-33-00.